Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Horizon Therapeutics
(NQ:
HZNP
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 5, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Horizon Therapeutics
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
16
17
Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 30, 2022
Via
Benzinga
Crude Oil Rises Sharply; XPeng Shares Spike Higher
November 30, 2022
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 25 points on Wednesday.
Via
Benzinga
Arcimoto (FUV) Stock Falls After 1-for-20 Reverse Split
November 30, 2022
Arcimoto (FUV) stock isn't doing so hot as the EV company's shares are falling following a one-for-20 reverse stock split.
Via
InvestorPlace
Why Are Chinese EV Stocks XPEV, LI, NIO Up Today?
November 30, 2022
Chinese EV stocks are climbing higher on Wednesday and they have Xpeng (XPEV) earnings to thank for the positive movement.
Via
InvestorPlace
Workday, XPeng, Titan Machinery And Some Other Big Stocks Moving Higher On Wednesday
November 30, 2022
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
$100 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth This Much Today
November 30, 2022
Via
Benzinga
Why Horizon Therapeutics' Shares Rose 11.32% on Wednesday
November 02, 2022
The company released encouraging year-end guidance.
Via
The Motley Fool
Why Horizon Therapeutics Stock Is Skyrocketing Today
November 30, 2022
Three big drugmakers could be interested in acquiring Horizon.
Via
The Motley Fool
Why Is Horizon Therapeutics (HZNP) Stock Up 30% Today?
November 30, 2022
Horizon Therapeutics (HZNP) stock is rising higher on Wednesday following reports that the company is considering a buyout.
Via
InvestorPlace
US Stocks Mixed; Dow Drops 200 Points
November 30, 2022
U.S. stocks traded mixed this morning, with the Dow Jones dropping around 200 points on Wednesday.
Via
Benzinga
This Is What Whales Are Betting On Horizon Therapeutics
November 30, 2022
Someone with a lot of money to spend has taken a bearish stance on Horizon Therapeutics (NASDAQ:HZNP). And retail traders should know. We noticed this today when the big position showed up on publicly...
Via
Benzinga
iPhone Pro Shipments May Miss Consensus, Tesla Rival Charts Ambitious Expansion Plan In Mexico, Amazon Cloud Unit To Add More Employees: Top Stories Wednesday, Nov. 30
November 30, 2022
Reuters
Via
Benzinga
Recap: Horizon Therapeutics Q3 Earnings
November 02, 2022
Horizon Therapeutics (NASDAQ:HZNP) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Horizon Therapeutics Shares Jump On Confirmation Of Takeover Talks With Several Large Companies
November 30, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 30, 2022
Via
Benzinga
Why Horizon Therapeutics Shares Are Trading Higher By Over 30%; Here Are 32 Stocks Moving Premarket
November 30, 2022
Gainers Kalera Public Limited Company (NASDAQ: KAL) shares rose 33.3% to $0.2399 in pre-market trading after jumping 45% on Tuesday. Kalera recently announced restructuring process for German...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
November 30, 2022
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about for Wednesday!
Via
InvestorPlace
Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi
November 29, 2022
The three companies have until Jan. 10 to decide whether they want to buy Horizon.
Via
Investor's Business Daily
Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer
November 29, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
November 16, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
November 16, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November
November 10, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
November 08, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
November 05, 2022
From
Horizon Therapeutics plc
Via
Business Wire
United Therapeutics, Super Micro Computer, Novo Nordisk And Other Big Gainers From Wednesday
November 03, 2022
U.S. stocks closed lower on Wednesday, with the Dow Jones dropping more than 500 points. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations
November 02, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics Does Not Have Meaningful Upside, Analyst Initiating Coverage Says
November 01, 2022
Via
Benzinga
Horizon Therapeutics plc Named to the Seramount Inclusion Index
November 01, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis
October 27, 2022
From
Horizon Therapeutics plc and Q32 Bio
Via
Business Wire
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.